|
Penicillin Prophylaxis in Sickle Cell Disease (PROPS) Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Penicillin Prophylaxis in Sickle Cell Disease (PROPS) conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Penicillin Prophylaxis in Sickle Cell Disease (PROPS) Clinical research trials and Penicillin Prophylaxis in Sickle Cell Disease (PROPS) health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Penicillin Prophylaxis in Sickle Cell Disease (PROPS). Penicillin Prophylaxis in Sickle Cell Disease (PROPS) Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Penicillin Prophylaxis in Sickle Cell Disease (PROPS) clinical trial. Subjects frequently get the best healthcare possible for their Penicillin Prophylaxis in Sickle Cell Disease (PROPS) condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Penicillin Prophylaxis in Sickle Cell Disease (PROPS)  Penicillin Prophylaxis in Sickle Cell Disease (PROPS)
Penicillin Prophylaxis in Sickle Cell Disease (PROPS)
For Condition: Anemia, Sickle Cell,Hematologic Diseases,Hemoglobinopathies,Infection (S. pneumoniae),Pneumonia
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine whether the regular daily administration of oral penicillin would reduce the incidence of documented infection due to Streptococcus pneumoniae in children with sickle cell anemia.
Details: BACKGROUND: For over 20 years children with sickle cell anemia have been known to have an increased susceptibility to severe bacterial infection, particularly due to Streptococcus pneumoniae. Meningitis, pneumonia and septicemia due to this organism have been recognized as the major causes of death for these children, with children under three years of age being at highest risk. The annual incidence of pneumococcal septicemia among young children with sickle cell anemia appears to have remained remarkably constant over the last two decades at approximately 10 percent. This illness can often be fulminant, progressing from the onset of fever to death in less than 12 hours, with a case fatality rate ranging as high as 35 percent. Penicillin prophylaxis has been advocated as a preventive measure against severe pneumococcal infections in children with sickle cell anemia. One study had shown that the risk of pneumococcal infection in these children could be reduced by the use of parenteral penicillin. DESIGN NARRATIVE: Phase I was a multi-center, randomized, double-blind, placebo-controlled trial. One hundred and five patients were assigned to the penicillin group and 110 to placebo. The primary endpoint was a documented severe infection due to S. pneumoniae. The secondary endpoint was a severe infection due to an organism other than S. pneumoniae. Because data were not available to define the age at which prophylactic penicillin could be safely discontinued, the NHLBI launched Phase II of the Prophylactic Penicillin Study beginning in 1987. Recruitment ended in August, 1993. The clinical phase of Phase II ended in August, 1994. Phase II was a multi-center randomized trial to evaluate the hazards of discontinuing daily oral penicillin at the age of five years. Within three months of their fifth birthdays, all children were randomized to continue oral penicillin prophylaxis or to stop prophylaxis. Each child was followed for a minimum of two years. The primary endpoint was a comparison of documented pneumococcal infection in children continuing penicillin after five years of age versus children whose prophylaxis was stopped at five years of age. Ancillary studies conducted in subsets of patients included: the prevalence of colonization of the nasopharynx with antibiotic resistant microorangisms; and the relationship of antibody response to pneumococcal vaccination to the incidence of pneumococcal sepsis in this patient population.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: /5 Years
Genders: Both
Protocol Entry Criteria: In the Phase I trial, Black children with sickle cell anemia aged 3 months to 3 years. In the Phase II trial, children with sickle cell anemia aged five years 3 months of age and younger who had received prophylactic penicillin for at least two yea
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DavidBecton, , University of Arkansas
Additional Information:
Study ID Numbers: 305;
Study Start Date: August 1983
Record last reviewed: October 1994
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000585
Other Pneumonia Studies:
1. Trial to Reduce Alloimmunization to Platelets (TRAP)
2. Cord Blood Stem Cell Transplantation Study (COBLT)
3. Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)
4. Penicillin Prophylaxis in Sickle Cell Disease (PROPS)
5. A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy with GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
Related Studies:
Other Pneumonia Clinical Trials
Other Clinical Trials
Other Clinical Trials
Penicillin Prophylaxis in Sickle Cell Disease (PROPS)
|
|
|
|
|
|
|
|
